The Relevance of Hereditary Cancer Risks to Precision Oncology: What Should Providers Consider When Conducting Tumor Genomic Profiling?
Through tumor genomic profiling (TGP), existing and novel treatments can be selected to better target the specific dysregulated molecular pathways that drive growth and spread of a patient's tumor. Although the primary purpose of TGP is to detect targetable somatic mutations for treatment, TGP may also uncover germline mutations with important implications for patients and family members. Oncology care providers should be aware of the hereditary cancer risks associated with genes commonly tested by TGP. Further, patients should be informed about the possible discovery of hereditary cancer risk information and the relevance of this information to their health and that of family members, and should have their preferences toward further evaluation of hereditary risk information that could be revealed by TGP documented in the medical record and followed.
Fox Chase Cancer Center,  Philadelphia Pennsylvania
Rishi
R
Jain
Fox Chase Cancer Center,  Philadelphia Pennsylvania
Michelle J
MJ
Savage
Fox Chase Cancer Center,  Philadelphia Pennsylvania
Andrea D
AD
Forman
Temple University School of Medicine, Philadelphia Pennsylvania
Reetu
R
Mukherji
Fox Chase Cancer Center,  Philadelphia Pennsylvania
Michael J
MJ
Hall
D023281:Genomics / Q000379:methods*; D006801:Humans; D008495:Medical Oncology / Q000379:methods*; D057285:Precision Medicine / Q000379:methods*